A PYMNTS Company

Antitrust Chronicle® – Patents, Drugs & Antitrust

Spring 2014, Volume 4, Number 2

Dear Readers, This issue looks at four health issues recently argued by the FTC. First, we deal with the FDA’s REMS (risk evaluation and mitigation strategies) program and how it seems to conflict with the FTC’s desire to encourage generic competition. The FTC is examining branded pharmaceutical firms’ refusal to sell samples of restricted distribution […]

Read More

In case you missed it...



April

This Chronicle explores the rapidly evolving intersection of foreign direct investment and technology, a space where traditional assumptions about openness, control, and market integration are being fundamentally reworked.




March

This Chronicle brings together contributions that explore the evolving relationship between industrial policy, competition, regulation & technological change from complementary angles.




February

This month’s TechREG Chronicle focuses on online consumer protection, at a moment when regulators on both sides of the Atlantic are reassessing how legacy consumer-protection frameworks apply in digital, data-driven markets.


See more Chronicles by year: